Answer： Like the original research drug, generic drug manufacturers should conduct signal testing on suspected adverse drug reaction information collected through various channels to timely discover new drug safety risks. In addition, establishing a sound drug vigilance system, process, and management system is the foundation for implementing signal detection and risk control. Generic drug manufacturers can pay attention to the safety information changes in the original product instructions, pay attention to the announcement notices and alert alerts issued by drug regulatory agencies, and use the information of the original or similar drugs to help themselves better identify signals and implement risk control.